Table 2.
Association between P/LP mutations and SN
| Variable | Any solid SN | |
|---|---|---|
| aOR (95% CI)** | p-value* | |
| P/LP mutations | ||
| No (427 cases; 587 controls) | Ref | |
| Yes (72 cases ; 38 controls) | 4.26 (2.36 – 7.69) | <0.001 |
| Age at diagnosis of primary cancer | ||
| Per year increase | 1.01 (0.97 – 1.05) | 0.66 |
| Sex | ||
| Male | Ref | |
| Female | 1.58 (1.15 – 2.18) | 0.005 |
| Radiation | ||
| No | Ref | |
| Yes | 26.47 (9.67 – 72.47) | <0.001 |
| Anthracyclines | ||
| No | Ref | |
| Yes | 1.3 (0.8 – 2.1) | 0.29 |
| Platinum compounds | ||
| No | Ref | |
| Yes | 2.11 (1.28 – 3.5) | 0.004 |
Abbreviations: SN: subsequent neoplasm; P/LP: pathogenic/ likely pathogenic; aOR: adjusted odds ratio; 95%CI: 95% confidence interval
*
P-values were calculated using multivariable conditional logistic regression model adjusted for P/LP mutation status, age of primary cancer diagnosis, sex, year of primary cancer, radiation (y/n), anthracycline exposure (y/n), platinum compounds exposure (y/n) and principal components.
**
adjusted for year of primary cancer diagnosis